Search Results for: Biotech Merger Acquisition Deal Activity
Articles
Biotech Merger & Acquisition Deal Activity Skyrockets in Early 2018 February 12, 2018
One month into 2018, biotech merger and acquisition (M&A) deal activity has already skyrocketed. Acquisitions from colossal drug makers, Celgene...Global Gene Therapy Deals Sky-Rocketed to Nearly $5 Billion in 2014 June 25, 2015
The total number of deals in the global gene therapy market more than doubled from 16 in 2013 to 36...Q1 2015 Global Pharma, Medical & Biotech Trend Report April 22, 2015
Mergermarket has released its Global Pharma, Medical & Biotech (PMB) trend report for the first quarter (Q1) of 2015. Take...A Rise in IPOs Revive Investments for Global Pharma & Biotech Industry June 3, 2014
The heightened private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008-2010,...A Rise in IPOs Revive Investments for Global Pharma & Biotech Industry May 29, 2014
The heightened private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years,...QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals November 14, 2023
QSAM Biosciences Inc. has signed a non-binding term sheet with Telix Pharmaceuticals (US) Inc., a subsidiary of Telix Pharmaceuticals Limited providing material terms for the acquisition of the company by….
REAL ESTATE - How Biopharma M&A Can Uncover Hidden Value in Real Estate January 13, 2021
Roger Humphrey, MBA, says a new era of deal-making is accelerating breakthrough therapy development, making now a prime time to look for breakthrough real estate and facilities concepts as well.
CYBERSECURITY - Why Pharmaceutical Companies Are Vulnerable to Cyberattacks & What You Can Do to Protect Your Company January 13, 2020
Andrew Douthwaite says having a comprehensive cybersecurity strategy in place to safeguard digital assets has become an essential part of any company’s security protocols, and not doing so leaves valuable data vulnerable.
EXECUTIVE INTERVIEW - Vetter: Insights on Insourcing Versus Outsourcing in the World of Injectable Manufacturing January 8, 2019
Oskar Gold, Vetter’s Senior VP, Key Account Management and Marketing/Corporate Communications, offers his insights on aseptic manufacturing and why careful thought and consideration of different criteria must be applied.
CRO MARKET - CRO Sector: Sales & Margins Remain Healthy January 7, 2016
Adam Dion, MSc, indicates declining R&D productivity and increased development costs have negatively impacted biopharmaceutical companies, and the need for them to maximize productivity and lower costs in their commercial operations will cause them to look to CRO partners as they enter into outsourcing arrangements.
MARKET BRIEF - Sequestration Haunts Life Science Research Tool Market Into 2014 July 8, 2014
Christi Bird, Senior Industry Analyst, Frost & Sullivan, believes the bleakest outlook provided for the life sciences industry is one without a clear light at the end of the tunnel, and successful companies will buckle down to determine long-term strategies for beating the lackluster numbers expected from a sustained austerity policy.
11/14/2012 November 8, 2012
A Note to The Pharmaceutical Industry Upon The Re-Election of Barack Obama By: Matthew Herper, Forbes Staff, mherper@forbes.com I've covered...3/6/2012 February 29, 2012
Avanir & Concert Announce Exclusive License Agreement Avanir Pharmaceuticals, Inc. and Concert Pharmaceuticals, Inc. recently announced they have entered into...1/17/2012 January 12, 2012
NantWorks to Invest $85.5 Million, Creating New Jobs & Drugs California-based NantWorks, LLC, recently announced plans to locate a new...
